45 results about "Glial cell line-derived neurotrophic factor" patented technology

The invention discloses a chitosan artificial nerve graft containing a neurotrophic factor and a preparation method thereof. The chitosan artificial nerve graft is prepared by processing chitosan into a nerve conduit with a porous structure and high tensile strength by virtue of weak acid dissolution, mold injection, freezing formation, neutralization and immobilization, cleaning, lyophilization and other processes under a condition of not adding any foaming agent or cross linking agent. The cell factor with a treatment effect in the nerve conduit is one or more of a basic fibroblast growth factor (bFGF), a brain derived neurotrophic factor (BDNF), a neurotrophic factor 3 (NT-3), a basic fibroblast cell growth factor (bFGF) and a glial-cell-line derived neurotrophic factor (GDNF) and the like. The product provided by the invention contains the neurotrophic factor, adopts degradable materials, and has excellent biocompatibility with a human body. The prepared product does not contain exogenous toxic or side-effect substances brought by a preparation process.

The invention belongs to the field of biological engineering and provides a method for separating human spermatogonial stem cells. The method comprises the following steps of: mechanically separating a testicular tissue; processing the testicular tissue into a semi-liquid state; adding digestive enzyme solution I into the liquid testicular tissue in the semi-liquid state; digesting the testiculartissue into a single convoluted tubule; adding digestive enzyme solution II in the convoluted tubule; digesting the convoluted tubule into a single cell; separating reproductive cells from supportingcells in the single cell; separating G protein-coupled receptor 125 (GPR125) positive spermatogonial stem cells from glial cell line-derived neurotrophic factor (GDNF) family receptor alpha 1 (GFRA1)positive spermatogonial stem cells by adopting an immunomagnetic bead cell sorting method; and identifying the separated GPR125 positive spermatogonial stem cells and the GFRA1 positive spermatogonial stem cells by adopting an immune cell chemical method. By the method, a large number of the high-purity human spermatogonial stem cells are obtained, and sufficient cell sources are provided for theresearch of the human spermatogonial stem cells and the application of the human spermatogonial stem cells in regenerative medicine and reproductive medicine.

A method of treating Parkinson's disease in humans is disclosed, wherein glial cell-line derive neurotrophic factor (GDNF) is chronically administered directly to one or both putamen of a human in need of treatment thereof via convection-enhanced infusion using at least one implantable pump and at least one catheter. In one aspect of the present invention the GDNF is infused directly into one or both putamen through one or more indwelling intraparenchymal mutitiport brain catheters connected to one or moreimplantable pumps wherein the flow rate is pulsed.

The present invention relates to an in vitro method for identifying a molecule, which interferes with the interaction between a glial cell-line derived neurotrophic factor family ligand (GFL) and a heparan sulfate proteoglycan (HSPG), by screening a library of molecules against a matrix anchored complex comprising at least one immobilized glial cell-line derived neurotrophic factor family ligand (GFL) and at least one heparan sulfate proteoglycan (HSPG), wherein the interfering molecule is isolated based on its capacity to replace a glial cell-line derived neurotrophic factor family ligand (GFL) in said anchored complex. The invention also relates to a complex for identifying such a molecule. The invention also relates to methods for preventing or delaying a neurodegenerative process as well as to method for prophylactic treatment or treatment of a disorder in the nervous system.

The present invention relates to devices comprising a composition of human cells secreting a therapeutically effective amount of GDNF (Glial cell-line-derived neurotrophic factor) encapsulated in a device comprising a core and a semipermeable membrane allowing for the diffusion of GDNF protein. The human cells are from one cell line.

The invention belongs to the field of biological medicines, particularly a deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor for treating Parkinson's disease. By carrying out partial delection mutation on an N terminal of the deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor, the obtained deletion type recombinant human mesencephalic astrocyte-derived neurotrophic factor has the characteristic of higher activity.

The present invention relates to the use of novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), for treating brain diseases and injuries that result in dopaminergic deficiencies and mitochodrial dysfunction, e.g., reduced complex I enzyme activity.

The invention belongs to the field of biological engineering and provides a method for separating human spermatogonial stem cells. The method comprises the following steps of: mechanically separating a testicular tissue; processing the testicular tissue into a semi-liquid state; adding digestive enzyme solution I into the liquid testicular tissue in the semi-liquid state; digesting the testicular tissue into a single convoluted tubule; adding digestive enzyme solution II in the convoluted tubule; digesting the convoluted tubule into a single cell; separating reproductive cells from supporting cells in the single cell; separating G protein-coupled receptor 125 (GPR125) positive spermatogonial stem cells from glial cell line-derived neurotrophic factor (GDNF) family receptor alpha 1 (GFRA1) positive spermatogonial stem cells by adopting an immunomagnetic bead cell sorting method; and identifying the separated GPR125 positive spermatogonial stem cells and the GFRA1 positive spermatogonial stem cells by adopting an immune cell chemical method. By the method, a large number of the high-purity human spermatogonial stem cells are obtained, and sufficient cell sources are provided for the research of the human spermatogonial stem cells and the application of the human spermatogonial stem cells in regenerative medicine and reproductive medicine.

The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

The invention discloses a pharmaceutical composition containing GDNF for treating corneal epithelial injury, the pharmaceutical composition contains GDNF (preferably human source), and preferably further contains OPG (preferably human source). The pharmaceutical composition of the present invention (preferably in the form of eye drops) can not only promote the proliferation and clone formation ability of limbal stem cells, but also effectively promote the repair of corneal epithelial damage, including the repair of persistent corneal epithelial damage, diabetic keratopathy Treatment, treatment of neurokeratitis, treatment of limbal stem cell deficiency.

The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.

The present invention relates to a compound that includes a peptide vector, such as angiopep-2 which acts as a carrier across the blood-brain barrier, linked to glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), or a related molecule, such as an analog or a fragment thereof. The compounds of the invention may be used to treat any disease where increased neuronal survival or growth is desired, e.g., neurodegenerative diseases, such as Parkinson's disease or amyotrophic lateral sclerosis. Other diseases can be treated using the compounds include schizophrenia and depression.